Skip to main content

Posts

Showing posts with the label parvovirus B19

Notes from the Field: #Parvovirus B19 #Activity — #USA, January 2024–May 2025 (MMWR)

Summary -- What is already known about this topic? - Parvovirus B19 (B19) is a respiratory virus that can cause adverse fetal outcomes in pregnant women and persons who are immunocompromised or have chronic hemolytic blood disorders . After relatively low rates during the COVID-19 pandemic years of 2021–2023, B19 activity in 2024 exceeded that of prepandemic years. -- What is added by this report? - Data from the National Syndromic Surveillance Program indicated that the proportion of sera specimens positive for B19 antibodies during January–May 10, 2025, was higher than during the same period in 2024 , suggesting a sustained increase in B19 transmission. -- What are the implications for public health practice? - Health care providers should have a heightened suspicion of and consider providing testing for B19 infection among groups at high risk for severe outcomes, including pregnant women with compatible symptoms or exposure to B19. Among pregnant women, health care providers should ...

Insights into the #clinical and molecular #epidemiology of an infections #outbreak of human #parvovirus B19 in #France, 2023-2024

Highlights •  A large B19V French outbreak of an unexpected magnitude occurred, with a monthly rate that has reached 21.4%. •  During this outbreak, 50% of infected pregnant women exhibited fetal complications. •  Phylogenetic analysis revealed the co-circulation of several B19V lineages of genotype 1a, the main epidemic lineage of which emerged in 2017. Abstract Background The human parvovirus B19 (B19V) infections cycle occurs in 3- to 4-year periods and is responsible for benign childhood erythema infectiosum . It is also associated with transient aplastic crisis in patients with underlying hemolytic diseases and with severe fetal sometimes fatal infection . This study investigated the epidemiological, clinical and molecular characteristics of an unusually large 2023-2024 outbreak of B19V. Methods . Laboratory-confirmed cases were retrospectively and prospectively recorded at the Clermont-Ferrand University Hospital, France , between January, 2018 and November, 2023 an...

Clinical #Features of #Human #Parvovirus B19-Associated #Encephalitis Identified in the #Dakar Region, #Senegal, and Viral Genome Characterization

Abstract Neurological manifestations associated with human parvovirus B19 (B19V) infections are rare and varied. Acute encephalitis and encephalopathy are the most common, accounting for 38.8% of all neurological manifestations associated with human B19V. Herein, we report on the clinical features of 13 laboratory-confirmed human cases of B19V-associated encephalitis in Senegal in the framework of a hospital-based surveillance of acute viral encephalitis conducted from 2021 to 2023. Overall, B19V was detected from 13 cerebrospinal fluid samples using specific real time PCR. The mean age was 16.7 years among B19V-positive patients, with a higher prevalence in 0–5-year-old children and the sex ratio (male/female) was 2.25. The B19V-positive patients mainly exhibited hypoleukocytosis, normal glycorrhachia, and normal proteinorrachia in the cerebrospinal fluid. While the main neurological symptoms included meningeal and infectious syndromes . Furthermore, three complete B19V genome sequenc...